<AD>

<WIRE> Genetic Signatures (ASX:GSS) Anticipates Influenza B Detection to Loom Over Quarterly Sales



Genetic Signatures has announced that the detection of influenza B is expected to influence its quarterly sales.

In response to the situation, Genetic Signatures (ASX:GSS) has undertaken an investigation.

The issue, which is unique to the influenza B virus, is reportedly close to being resolved.

It was revealed that this season’s influenza B virus is not being consistently detected in a low portion of samples with low viral concentrations.

At present, Genetic Signatures (ASX:GSS) expects its forecast revenue to approximate A$2 million for Q1 of FY2023.

Meanwhile, the detection of the influenza A virus remains unaffected.

In the meantime, the current quarter’s sales of Genetic Signatures' Easyscreen™ respiratory pathogen detection kit have been impacted.

Genetic Signatures (ASX:GSS) is a biotech firm that specializes in the development of diagnostics for the rapid detection of infectious diseases.


View full chart on Save $30 on a Pro or Premium TradingView account

Save $30 on a Pro or Premium TradingView account


Supported by

<SPON> Trade share CFDs with Plus500



Global online trading services company, Plus500:

Plus500 trading platform allows you to trade shares from all popular markets such as USA, UK, Germany and more, with leverage and low spreads. Using our advanced trading tools, you can also control your profits and losses.

Plus500AU Pty Ltd, AFSL #417727 issued by Australian Securities and Investments Commission. Based in Sydney.

LINK


Subscribe to the newsletter

Receive whispers every day in your inbox.